Edesa Biotech, Inc.

Edesa Biotech, Inc. is currently overvalued and classified as "does not qualify" due to significant financial concerns, with key ratios indicating weak valuation metrics and a 54.34% decline in stock price over the past year compared to a 10.26% gain in the S&P 500.

As of June 4, 2025, the technical trend has shifted to a bearish stance with moderate strength, driven by bearish daily moving averages and KST signals, despite a mildly bullish MACD.

As of March 2022, the management team of Edesa Biotech, Inc. includes Independent Chairman Mr. Sean MacDonald, CEO Dr. Pardeep Nijhawan, Directors Mr. Frank Oakes, Dr. Lorin Johnson, Mr. Paul Pay, and Mr. Carlo Sistilli. They oversee the company's strategic direction and operations.

Edesa Biotech, Inc. is a micro-cap biopharmaceutical company focused on developing clinical-stage drugs for dermatological and gastrointestinal conditions. As of March 2025, it reported a net profit loss of $2 million and has a market cap of $14.12 million.

As of Jun 18, Edesa Biotech, Inc. has a market capitalization of 14.12 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -5.84 million over the latest four quarters. As of Sep 24, the company reported shareholder's funds of 1.98 million and total assets of 3.94 million.